According to Zacks, “Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. “
Several other research analysts have also recently weighed in on the stock. BidaskClub raised shares of Mirati Therapeutics from a hold rating to a buy rating in a research report on Wednesday, November 13th. Credit Suisse Group set a $115.00 price target on shares of Mirati Therapeutics and gave the company a buy rating in a research report on Friday, September 27th. B. Riley lowered their price target on shares of Mirati Therapeutics from $92.00 to $83.00 and set a neutral rating on the stock in a research report on Wednesday, September 11th. Guggenheim boosted their price target on shares of Mirati Therapeutics from $116.00 to $128.00 and gave the company a buy rating in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group raised shares of Mirati Therapeutics from a hold rating to a buy rating and upped their target price for the company from $89.00 to $105.00 in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company’s stock. Mirati Therapeutics currently has a consensus rating of Buy and a consensus target price of $105.67.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.25) by ($0.13). The firm had revenue of $0.99 million for the quarter, compared to analyst estimates of $0.50 million. Mirati Therapeutics had a negative net margin of 2,698.66% and a negative return on equity of 48.60%. As a group, equities research analysts expect that Mirati Therapeutics will post -5.36 EPS for the current fiscal year.
In other Mirati Therapeutics news, Director Michael G. Grey sold 3,042 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $102.44, for a total value of $311,622.48. Following the transaction, the director now owns 5,298 shares of the company’s stock, valued at $542,727.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce L. A. Carter sold 3,000 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $89.24, for a total transaction of $267,720.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $267,720. The disclosure for this sale can be found here. Insiders sold 57,852 shares of company stock worth $5,046,401 in the last ninety days. 4.70% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of MRTX. Aperio Group LLC purchased a new stake in Mirati Therapeutics during the second quarter worth about $50,000. NumerixS Investment Technologies Inc purchased a new stake in Mirati Therapeutics during the second quarter worth about $52,000. Quantamental Technologies LLC purchased a new stake in Mirati Therapeutics during the second quarter worth about $59,000. First Mercantile Trust Co. purchased a new stake in Mirati Therapeutics during the second quarter worth about $89,000. Finally, Tower Research Capital LLC TRC purchased a new stake in Mirati Therapeutics during the third quarter worth about $112,000.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.